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Abstract
Background: Bipolar disorder is recognized as a major mental health issue, and its economic
impact has been examined in the United States. However, there exists a general scarcity of
published studies and lack of standardized data on the burden of the illness across European
countries. In this systematic literature review, we highlight the epidemiological, clinical, and
economic outcomes of bipolar disorder in Europe.
Methods: A systematic review of publications from the last 10 years relating to the burden of
bipolar disorder was conducted, including studies on epidemiology, patient-related issues, and
costs.
Results: Data from the UK, Germany, and Italy indicated a prevalence of bipolar disorder of ~1%,
and a misdiagnosis rate of 70% from Spain. In one study, up to 75% of patients had at least one
DSM-IV comorbidity, commonly anxiety disorders and substance/alcohol abuse. Attempted suicide
rates varied between 21%–54%. In the UK, the estimated rate of premature mortality of patients
with bipolar I disorder was 18%. The chronicity of bipolar disorder exerted a profound and
debilitating effect on the patient. In Germany, 70% of patients were underemployed, and 72%
received disability payments. In Italy, 63%–67% of patients were unemployed. In the UK, the annual
costs of unemployment and suicide were £1510 million and £179 million, respectively, at 1999/2000
prices. The estimated UK national cost of bipolar disorder was £4.59 billion, with hospitalization
during acute episodes representing the largest component.
Conclusion: Bipolar disorder is a major and underestimated health problem in Europe. A number
of issues impact on the economic burden of the disease, such as comorbidities, suicide, early death,
unemployment or underemployment. Direct costs of bipolar disorder are mainly associated with
hospitalization during acute episodes. Indirect costs are a major contributor to the overall
economic burden but are not always recognized in research studies.
Background
Our knowledge of the burden of bipolar disorders is based
primarily on evidence from the United States. The lifetime
prevalence of bipolar disorders in 2005 was estimated at
3.9% [1]. In a US population screen, 31.2% of individuals
with positive screens on the Mood Disorder Question-
naire (MDQ) for bipolar I or II disorders, had previously
received a diagnosis of unipolar depression [2]. Another
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US patient survey showed a 69% rate of misdiagnosis, pri-
marily for MDD, among patients with bipolar disorder
[3]. This high rate of misdiagnosis most likely makes these
prevalence estimates of bipolar disorder conservative.
Aside from the diagnosis itself, comorbidity, disability,
unemployment, and suicide further add to the burden of
the disease. Approximately 65% of people diagnosed with
bipolar disorder have at least 1 other psychiatric ailment,
with anxiety, substance abuse, and other mood disorders
among the most common [4,5]. Other comorbidities
including injury, poisoning, and mental and nervous sys-
tem disorders are estimated to contribute a mean cost of
US $2036 per patient [6]. Patients with bipolar disorder
are also at higher risk of premature mortality with 1 in 5
patients committing suicide [7]. Total bipolar/affective
disorder treatment and management costs in the US in
2003 were estimated at $US 30.4 to 43.7 billion (using
1990 values) [8]. The lifetime direct cost of bipolar disor-
der was estimated at $13 billion in 1998 [9] and the direct
cost of managing a single patient was estimated at more
than $3400/year in 1999 [10]. Carta and Angst [11] have
argued that "the financial implications of bipolar disorder
are only just beginning to be taken into account." They
also highlight a lack of data on indirect costs, which are
presumed to be significant. The recognition of bipolar dis-
order as a major mental health issue is best exemplified by
STEP-BD (Systematic Treatment Enhancement Program
for Bipolar Disorder), a current large scale study across the
US.
Given the differences between US and European health
care systems, clinical practices, health research policy-
making, and payer environments, we undertook this liter-
ature review to determine the epidemiological, clinical,
and economic burden of bipolar disease in Europe.
Methodology
Overview
We conducted a systematic review of the literature for
publications on issues pertinent to the burden of bipolar
disorder, including epidemiology (prevalence, incidence,
misdiagnosis), patient-related issues (disability, unem-
ployment, comorbidity, mortality, suicide, functional and
symptomatic recovery), and costs (direct, indirect, intan-
gible, and other). We also reviewed health technology
assessments (HTA) and treatment guidelines.
Literature search
For all areas of interest, we searched MEDLINE, EMBASE,
and BIOSIS databases and conducted a general Google
search. For cost issues, the National Health Service Eco-
nomic Evaluation Database (NHS EED) was also used.
The search terms for all issues included "bipolar disorder"
(MeSH or EMTREE heading), "Europe," "UK," "France,"
"Germany," "Italy," "Spain," and "Sweden" combined
with terms for the issues of interest. These terms included
"prevalence," "incidence," "epidemiology," "disab$,"
"incapacit$," "$employ$," "comorbid$," "concomitant
condition," "function$" and "symptom$ recovery,"
"prognosis," "suicide," "case fatality," "mortality,"
"death," "misdiagnosis," "incorrect diagnosis," "undiag-
nosed," "under diagnosed," "cost," "economic or finan-
cial burden," "resource use," "hospitalization," "quality of
life," "productivity loss," "absence," "off work or school,"
"crime," "criminal justice system" and "marriage."
We included observational and cost studies conducted
during the past 10 years in the UK, France, Germany, Italy,
Spain, and Sweden, with abstracts published in English or
French since the reviewers were fluent in both languages.
Reviews, case studies and studies relating to treatment
outcome were excluded. During data extraction, quality
was assessed using criteria based on Prins et al [12] for epi-
demiology, Downs and Black [13] for observational stud-
ies, and Cooper [14] for cost studies.
We also searched the Web sites of health technology
assessment bodies such as NICE (National Institute for
Health and Clinical Excellence], the SMC (Scottish Medi-
cines Consortium], IQWIG (Institute for Quality and Effi-
ciency in Healthcare), the LFN (Pharmaceutical Benefits
Board) in Sweden, the Transparency Commission in
France, the AIFA (Agenzia Italiana del Farmaco) in Italy,
the NHS EED, the HEED (Health Economic Evaluation
Database) and the CRD (Centre for Reviews and Dissem-
ination) for HTAs, recommendations and treatment
guidelines.
Results
Overall, 7 epidemiology studies, 14 studies on other
related issues in the bipolar population, 1 misdiagnosis
study, and 4 cost studies met the predefined inclusion cri-
teria (Table 1) [15-39].
Epidemiology
Data from the UK, Germany, and Italy indicated that the
prevalence of bipolar disorder in European countries was
around 1%. Prevalence ranged between 0.6% to 1% in
Germany and 0.8% in Italy. In the UK, the first-episode
incidence over 2 years was estimated at 4% to 4.6% in 3
cities and at 0.01% over 3 years in another area [21]. In
the cities, the age-related incidence of bipolar disorder
varied between 1.7% and 6.2% [20]. Faravelli et al [16]
found the prevalence of bipolar I and II disorder to be
0.5% and 0.4%, respectively.
There was strong evidence to show that bipolar disorder is
often misdiagnosed and that consequently, prevalence
and incidence rates are underestimated, as has been theClinical Practice and Epidemiology in Mental Health 2009, 5:3 http://www.cpementalhealth.com/content/5/1/3
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case in the USA [2,3]. A Spanish study by Baca-Garcia et al
[35] found that only 30% of patients with bipolar disor-
der were given a bipolar diagnosis on their first evalua-
tion.
Comorbidities
Fourteen studies showed evidence that patients with bipo-
lar disorder suffer from comorbidities (Table 2)
[15,16,22,24-34]. In particular, the evidence for concur-
rent mental disorders is strong compared with other con-
ditions. Up to 75% of patients with any bipolar disorder
had one or more Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) comorbidities [15].
More specifically, anxiety disorders and substance and
alcohol abuse appeared to be relatively common (16–
70% for anxiety disorders and 21–34% for substance
abuse disorders) among patients with bipolar disorder
although this finding was dependent on study inclusion
and exclusion criteria [22,26,27].
Mortality and suicide
Evidence for elevated suicide and premature mortality
rates also adds to the economic burden of bipolar disease
in Europe, primarily as a result of decreased productivity
levels. However, the evidence for mortality is poor com-
pared with that for suicide.
Dutta et al [23] reported death rates of 18% for bipolar I
disorder patients in the UK and 3–7% suicide rate
(although this was only 8 individuals in total). Attempted
suicide rates varied between 21% and 54%. An Italian
study by Benedetti and colleagues [22] reported that 22%
of males and 54% of females with bipolar I disorder had
a history of suicide attempts. In a French study by Henry
et al [27], it was reported that 40% of bipolar patients had
attempted suicide at least once. Vieta et al [29] found that
38% of bipolar patients with a comorbidity had
attempted suicide compared with only 21% of patients
without a comorbidity.
Disability and unemployment
Dittmann and colleagues [25] found that only 30% of
patients with bipolar disorder in Germany were employed
full-time at a level that was appropriate for their qualifica-
tions. Other studies showed that between 52% and 59% of
bipolar patients had an occupation [27,29], while an Italian
study [40] found that 63% to 67% of patients with bipolar I
disorder were unemployed. This is supported by evidence
from a German study [26] which found that 72% of bipolar
I patients received disability payments. Das Gupta and col-
leagues estimated absenteeism rates of 8% [36].
Table 1: Studies included in the systematic review
Study Country Type of study Study population Sample size
Jacobi et al 2004 [15] Germany Prevalence survey General 4181
Faravelli et al 2006 [16] Italy Prevalence survey General 2363
Kennedy et al 2005 [17] UK Incidence survey General 120,000
Kennedy et al 2004 [18] UK Incidence survey General 120,000
Kennedy et al 2005 [19] UK Incidence survey General 120,000
Lloyd et al 2005 [20] UK Incidence survey General 1,631,462
Proctor et al 2004 [21] UK Incidence survey General 249,203
Benedetti et al 2007 [22] Italy Cohort BPI 72
Dutta et al 2007 [23] UK Cohort BPI 120,000
Daban et al 2006 [24] Spain Cohort BPI and BPII out-patients 300
Dittmann et al 2002 [25] Germany Cohort Bipolar disorder [BPI, BPII, NOS] or schizoaffective 
disorder [bipolar type]
152
Brieger et al 2007 [26] Germany Cross-sectional BPI inpatients 121
Henry et al 2003 [27] France Cross-sectional Bipolar disorder 318
Schiavone et al 2004 [28] Italy Cross-sectional Unipolar and bipolar disorder in-patients 300
Vieta et al 2001 [29] Spain Cross-sectional Remitted BPI out-patients 129
Pini et al 2003 [30] Italy Cross-sectional BPI in-patients 151
Benazzi 2006 [31] Italy Cross-sectional BPII 374
Benazzi 2003 [32] Italy Cross-sectional Unipolar and BPII outpatients presenting for major 
depressive episode
313
Benazzi 2004 [33] Italy Cross-sectional BPII and unipolar MDD patients 73
Benazzi 2003 [34] Italy Cross-sectional Depressive mixed state 433
Baca-Garcia et al 2007 [35] UK Cohort Bipolar affective disorder adults 1153
Das Gupta & Guest 2002 [36] UK Prevalence-based cost study Bipolar disorder 297,000
Finnern et al 2003 [37] UK Retrospective chart review BPI and BPII 134
Zelicourt et al, 2003 [38] France Prevalence-based cost study BPI 390,000
Olie & Levy 2002 [39] France Retrospective chart review Hospitalization following manic episodes 137
BPI, bipolar I disorder; BPII, bipolar II disorder; MDD, major depressive disorder; NOS, not otherwise specifiedClinical Practice and Epidemiology in Mental Health 2009, 5:3 http://www.cpementalhealth.com/content/5/1/3
Page 4 of 8
(page number not for citation purposes)
Chronicity
Bipolar disorder is a long-term disease with many recur-
rences expected during the patient's lifetime. Demo-
graphic studies showed that on average, patients with
bipolar disorder experienced an episode every few years.
Vieta et al [29] reported that at a mean age of 40 years, the
mean number of total episodes was 12 to 15. Brieger et al
[26] reported an average of 9 episodes during a mean of
17 years of illness, while Daban [24] quoted an average of
11 to 15 episodes dependent on the nature of the onset
episode. Dittmann and colleagues [25] found that in a
2.5-year follow-up period, only 27% of patients were free
from symptoms, but 56% had a recurrence.
Costs
There are very few published studies that help to measure
the burden of disease in monetary terms, especially in the
major European countries. However, despite the paucity
of data, available evidence indicates that the cost-of-ill-
ness is high. Only 4 cost-of-illness studies were identified
from the UK and France. The most extensive study [36],
including both direct and indirect costs, estimated UK
national costs of bipolar disorder at £4.59 billion (esti-
mated 2007 value).
In this study [36], the costs associated with hospitaliza-
tion of patients during acute episodes appear to represent
the largest share of direct costs, at £69 million per year.
This is supported by other studies, including 1 by Finnern
et al [37] which anticipated a substantial role for hospital-
ization costs, especially for manic patients, who were hos-
pitalized for an average of 65 days compared with 36 days
for depressive patients. In France in 1999, total hospitali-
zation costs were estimated at  2.75 billion [38].
However, when compared with the amalgamation of
other long-term direct costs (including GP visits, prescrip-
tions, tests, outpatient visits, psychiatric ward visits, com-
munity health teams, day hospitals, and special
hospitals), other factors add up to £130 million per year
[36]. Nonmedical long-term accommodation costs con-
tribute £67.8 million and day care costs £18.1 million per
year. Conversely, the cost of drugs was small relative to
other direct costs, representing 4% to 6% of the total [36].
The key study from the UK [36] also included indirect
costs of unemployment (£1510 million per year) and sui-
cide (£179 million), adding to the burden of bipolar dis-
ease.
HTA and guidelines
Limited evidence was available from HTA and guidelines.
A systematic review of the clinical and cost-effectiveness of
newer treatments for mania [41] found that the evidence
was too limited and the quality too poor to analyze fully
the comparative cost-effectiveness of treatments. A French
cost-effectiveness analysis [42] showed similar limitations
in quality of design and methodology.
A systematic review of the clinical and cost treatments for
preventing relapse in bipolar disorder in 2007 [43] con-
cluded that there was insufficient evidence to assess the
impact of treatments on suicide or mortality. In general,
HTA recommendations and guidelines in the UK and
France focused on the treatment of individual manic or
Table 2: Proportions of bipolar disorder patients with comorbidities
Study Country Outcome
Jacobi et al 2004 [15] Germany 75% DSM-IV comorbidities
Faravelli et al 2006 [16] Italy 28% GAD, 24% antisocial personality disorder, 16% PDA, 16% SP, 16% psychosis, 16% paranoid and 16% 
borderline personality disorder
Benedetti et al 2007 [22] Italy BPI comorbidities by gender F/M%:
67/70% anxiety disorder, 54/26% PD, 33/63% OCD, 12/33% history of substance disorder
Daban et al 2006 [24] Spain By manic/depressive onset:
22/27% Axis 1 comorbidity
17/24% Axis 2 comorbidity
Dittmann et al 2002 [25] Germany 36% comorbid Axis I disorder
Brieger et al 2007 [26] Germany 34% substance abuse disorders, 16% anxiety disorders and 22% personality disorders
Henry et al 2003 [27] France 21% substance abuse, 24% anxiety disorder(s), 16% PDA, 11% phobia and 3% OCD
Schiavone et al 2004 [28] Italy Borderline personality disorder (41%), narcissistic disorder (21%), dependency disorder (13%) and 
histrionic (10%)
Vieta et al 2001 [29] Spain 31% comorbid psychiatric diagnosis
Pini et al 2003 [30] Italy 23% comorbid PD and 16% comorbid SP/OCD
Benazzi 2006 [31] Italy 45(M)-59(F)% Axis I comorbidity
Benazzi 2003 [32] Italy 54% Axis I comorbidity
Benazzi 2004 [33] Italy 46% Axis I comorbidity
Benazzi 2003 [34] Italy 54% Axis I comorbidity
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; GAD, general anxiety disorder; PD, panic disorder; PDA, panic disorder 
with agoraphobia; OCD, obsessive-compulsive disorder; SP, social phobiaClinical Practice and Epidemiology in Mental Health 2009, 5:3 http://www.cpementalhealth.com/content/5/1/3
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depressive episodes or prevention of recurrence rather
than on general therapy for all phases of the disease.
Quality
The epidemiology studies all scored between 10 and 14
out of 18 based on the Prins [12] criteria, which evaluate
external (source population, eligibility criteria, response
rate, nonresponders, study period, and population char-
acteristics) and internal validity (prospective design,
measurement instrument, disease definition, reporting of
prevalence, and level of information).
The majority of the observational studies on other issues
relating to the burden of bipolar disorder also scored
between 10 and 14 out of 18 based on the Downs and
Black [13] criteria. The criteria included reporting (out-
comes, patients, loss-to-follow-up, interventions, con-
founders, findings, random variability of outcomes, and
probabilities), external validity (whether study was repre-
sentative and accounting for confounding, recruitment,
sample size, and loss-to-follow up) and internal validity
(bias of sub-group analysis, follow-up length, statistical
analysis, and measures). Sample selection and its report-
ing were generally poor.
The cost-of-illness studies were evaluated in terms of the
presence of 7 key criteria: viewpoint, population, medical/
nonmedical costs, morbidity/mortality costs, discount-
ing, incremental/attributable, and sensitivity analysis.
One study [36] fulfilled 6 and 3 studies fulfilled 2 of the 7
criteria fully [37-39].
Discussion
Our review indicates that the lifetime prevalence of bipo-
lar disorder is approximately 1%. In the UK, the reported
incidence ranged from 0.01% to 6.2%. This variation can
be accounted for by several factors, including the time
period over which data were collected, the location of
mental health services, and the accuracy and consistency
of the diagnosis and its coding in medical records. More
recent data from the USA show a lifetime prevalence of
3.9%.
The reported prevalence of comorbidities ranged from
31% to 75% for comorbid psychiatric disorders and 13%
to 28% for comorbid anxiety. The variation may be attrib-
utable to differences in evaluation, diagnosis, and report-
ing. There was insufficient information on case fatality,
symptomatic recovery, functional recovery, and disability
to make an analysis of the evidence. Even where evalu-
ated, data on levels of employment were difficult to com-
pare based on differing outcome measures. Evidence from
the USA reinforces the important impact of bipolar disor-
der on suicide and quality of life [3,44-46] but there is a
lack of similar evidence for Europe.
By its very nature, bipolar disorder represents a diagnostic
challenge. In this review, only one study evaluated misdi-
agnosis rates [35]. A rate of 30% was reported by Baca-
Garcia et al [35], which was lower than the USA values
reported by Hirschfeld and colleagues, in which 31% of
patients were misdiagnosed with MDD, 49% were undi-
agnosed with either MDD or bipolar disorder and 20%
were correctly diagnosed [2]. An earlier study by
Gonzalez-Pinto et al [47] reported that 31% of patients
were misdiagnosed with schizophrenia or a psychotic dis-
order at onset.
Two French studies demonstrated high direct medical
costs for mania episodes, including hospitalizations,
regardless of study design [38,39] Reported costs ranged
from  2.75 to £4.59 billion. UK and Dutch studies tried to
demonstrate the indirect costs using NHS registry and epi-
demiological data, respectively [36,48,49]. The yearly UK
estimate for indirect costs was £1510 million for unem-
ployment while the Dutch estimate was US$1370 million
including absence and inefficiency. Although the UK
study was more comprehensive in its scope, it was con-
ducted several years ago.
The true costs of bipolar disorder are likely to have been
underestimated due to methodological limitations in the
published articles. Limiting factors include incomplete
coverage of costs, lack of clinical guidelines for diagnosis
and treatment, reliance on public registries and literature
sources for data analyses, and lack of knowledge of actual
resource use in patients with bipolar disorder by stage, age
group, country, and health care provider. Lost workdays
due to sick leave, reduced working capacity, or death were
not included in all cost studies.
Evidence of the indirect and social burden of bipolar dis-
order can be gleaned from general figures of mental health
disorders. Statistics from the largest statutory health insur-
ance fund in Germany (AOK-Bundesverband) showed
that 24.9 individuals per 100,000 had at least 1 day of
absenteeism for affective psychosis in 1999. The mean
workday loss per individual was 46.8 days. A Spanish
study (OFISALUD 1998, cited from Kleinman [8]) esti-
mated that, in 1998, indirect costs represented almost
66% of the total costs of mental health disorders, with lost
productivity accounting for 64.5% of these costs. Suicide
and other causes related to mental disorders such as
organic/alcoholic psychoses and motor vehicle accidents
made up the remaining 35% [8].
A major issue related to the burden of bipolar disorder is
the role of cognitive dysfunction as a key mediator of dis-
ability. Cognitive functioning has been shown to be asso-
ciated with employment status among persons with
bipolar disorder [50]. Studies have identified verbal mem-Clinical Practice and Epidemiology in Mental Health 2009, 5:3 http://www.cpementalhealth.com/content/5/1/3
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ory [51], sustained attention [52], and executive function
[53] as the specific areas of cognitive dysfunction impli-
cated in bipolar disorder. The deficits have been noted in
patients in the acutely manic [54] and acutely depressed
[55] states. However, persistence of cognitive impair-
ments has also been observed in the euthymic non-acute
states of illness [51,56]. Therefore, people with bipolar
disorder may continue to experience occupational and
social disabilities even after they have experienced remis-
sion of symptoms. Given the need for full functional
recovery and the consequences of long-term disability,
cognitive functioning in bipolar disorder is an important
topic worthy of further study.
It is evident that the economic burden of bipolar disorder
is large. However, European evidence is scarce and patchy.
Even in the USA, Carta and Angst [11] highlight that cost
studies tend to focus on inpatient care, are influenced by
late diagnosis, and lack indirect cost data. They cite ranges
of $24 to 30 billion over a 1-year period. According to
Diabetes UK, the economic burden of diabetes is £3.5 bil-
lion a year in the UK [57], which is less than the £4.6 bil-
lion per year for bipolar disorder estimated in a UK study
[36]. Evidence from the Disease Control Priorities Project
2001, showed that annual losses in disability-adjusted life
years (DALYs) were similar for schizophrenia and bipolar
disorder [58]. However, schizophrenia appears to attract
more interest and attention.
This review may have been subject to some degree of bias
due to its focus on electronic databases such as MEDLINE,
EMBASE, and BIOSIS and language selection criteria. Bias
was minimized by including a "Google" search for refer-
ences and checking reference lists in the selected studies.
Conclusion
Data from the USA have identified bipolar disorder as a
major mental health issue and an area of large unmet clin-
ical need. There is a growing interest in the topic as exem-
plified by STEP-BD, which aims to improve knowledge
and treatment of the disease. Conversely, in Europe, a
paucity of evidence exists regarding the epidemiological,
clinical, and economic burden of the disease.
Available data suggest that bipolar disorder is a major
health problem. An estimated 1% of the population suf-
fers from the disorder, although misdiagnosis likely
underestimates the figure. Other issues may impact on the
burden of the disease, such as comorbidities, suicide, early
death, unemployment, or employment at a level below
their qualifications.
The costs of bipolar disorder are high. Direct costs are
mainly associated with hospitalizations, GP or outpatient
visits, and community care. Indirect costs (lost productiv-
ity in particular) are a major contributor to the burden of
disease but are not always recognized in research studies.
The burden of bipolar disorder to patients, health care sys-
tems, and society in Europe is large and to date has been
under-recognized. The costs are mainly due to long-term
indirect costs and not only to hospitalization during acute
episodes. Drug costs are relatively small by comparison.
Therapy that is effective in all phases of the disease and to
which patients adhere is essential for effective manage-
ment.
In addition, the methodology used in the studies included
in this systematic review was generally of limited depth.
While epidemiological studies are often based on retro-
spective reviews and nonrepresentative samples, cost
studies can vary widely and fail to include all costs associ-
ated with bipolar disorder.
The current state of evidence suggests that bipolar disorder
is not considered to be an important enough health issue
in Europe to warrant research. Despite the methodologi-
cal challenges pertinent to bipolar disorder in particular,
and to mental health in general, more research and sus-
tained interest in the disease area is needed.
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